Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and ... broader review of our performance by Murdo Gordon, Jay Bradner, and Peter Griffith.

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The company’s shares closed yesterday at $289.02.

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with obesity was placed on clinical hold by the U.S. Food and ...

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

THE closing date of the mandatory conditional cash offer made by property tycoon Gordon Tang and his wife Celine to acquire all units of Suntec Real Estate Investment Trust (Reit) has been extended to ...

PROPERTY tycoon Gordon Tang and his wife Celine have failed to take over Suntec Real Estate Investment Trust (Reit), as their shareholding fell short of the 50 per cent threshold as at the offer ...

Amgen (NASDAQ:AMGN) did what it was "supposed to do." By that, I mean it followed through on what its chart indicated it would do in response to earnings. I'll show what I mean below, but my ...

Anthony Gordon dropped a sneaky “stay humble” in his interview after Newcastle’s win over Arsenal on Wednesday. Gordon scored the second goal in the Magpies’ comfortable 2-0 win at St ...